2021
- Codagenix Announces Appointment of Two New Members to its Board of Directors PR Newswire
- Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies PR Newswire
- Codagenix Appoints Tyler Cook as Chief Financial Officer PR Newswire
- Intranasal COVID-19 vaccine demonstrates single-dose efficacy in preclinical studies, in parallel with achievement of Phase 1 clinical milestone PR Newswire
- Intranasal vaccines aim to stop COVID-19 where it starts C&EN
- Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand PR Newswire
- Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors PR Newswire
- Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls PR Newswire
- Developers seek to bypass needle for inoculation China Daily
- Codagenix Expands Senior Management Team With Three New Appointments PR Newswire
- Codagenix Secures U.S. Patent for Codon-Deoptimized RSV Vaccine Candidates PR Newswire
- Inhaling away the virus: Is the next generation of COVID vaccines on their way? ABC News
- Codagenix and Serum Institute of India Initiate Dosing in Phase 1 Trial of COVI-VAC, a Single Dose, Intranasal, Live Attenuated Vaccine for COVID-19 PR Newswire
2020
- Codagenix CEO speaking at “The Quest for a COVID-19 Vaccine” event
- Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19 PR Newswire
- Codagenix is a finalist in the Buzz of BIO competition!
- Codagenix Inc. Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus (RSV) PR Newswire
- Codagenix, Inc. Appoints Jeffrey Fu, Ph.D., Chief Business Officer PR Newswire
- Serum Institute of India Initiates Manufacturing of Codagenix’s Intranasal Live-Attenuated COVID-19 Vaccine Candidate PR Newswire
- Synthetic biologists have created a slow-growing version of the coronavirus to give as a vaccine MIT Technology Review
- What if the First Coronavirus Vaccines Aren’t the Best? New York Times
- Biotech Startup Codagenix Plans Human Trials for COVID-19 Vaccine BioSpace
- NIH Supports Codagenix’s Human Codon Deoptimized RSV Vaccine Via $2.2M Grant and a Renewed R&D Contract for Scale-up Manufacturing
- Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19 PR Newswire
- Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19 PR Newswire
- Gates vets at Adjuvant back Codagenix’s software-driven approach to recoding RSV, flu, oncolytic viruses and more Endpoints News
- Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products PR Newswire
2019
- Codagenix and USDA-ARS Renew CRADA for Continued Development of Synthetic, Multivalent Foot-and-Mouth Disease Virus (FMDV) Vaccine
- Codagenix presenting at ID Week
- Codagenix Inc. Strengthens Leadership Team with Experienced Chief Medical Officer
- Codagenix Inc. Announces Award of $1M US Army Contract for Continued Development of Contemporary, Balanced Dengue Vaccine
- Codagenix: Combating Deadly Diseases with a Fast Track to Vaccine Development Wired
2017
- RSV vaccine player Codagenix snags $3M in public and private investment FiercePharma
- Demonstration of Multi-Season Efficacy and Immunogenicity of CodaVax Intranasal Influenza Vaccine